CYP3A4 and peripheral neuropathy: It has been reported that the frequency of occurrence of chemotherapy-induced peripheral neuropathy due to vincristine, a CYP3A4 substrate, increased when aprepitant was used in combination with the CHOP regimen, and it is possible that aprepitant may contribute to an increase of vincristine-induced side effects [13].